Ziv-aflibercept

N/A

Report date: 2025/08/01 14:25:42

Base Information

Drug NameZiv-aflibercept
Drug Alias NameVEGF Trap (R1R2)Eylea pre-filled syringeVascular endothelial growth factor Trap-R1R2Vascular endothelial growth factor TrapVEGF Trap-Eye +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitorsVascular endothelial growth factor B inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor AVascular endothelial growth factor B
Therapy Area/IndicationsUveal melanomaMetastatic breast cancerSkin Melanoma +[53] 
Global Approved IndicationsColorectal Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/08/03
Country/TerritoryCzechiaBelgiumBulgaria +[53] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPending
Originator CompaniesRegeneron Pharmaceuticals IncSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofiSanofi-Aventis U.S. LlcSanofi Winthrop Industrie SA
Inactive CompaniesTanta UniversityNational Cancer InstituteRegeneron Pharmaceuticals Inc
Active IndicationsColorectal Neoplasms
Inactive IndicationsUveal melanomaMetastatic breast cancerSkin Melanoma +[52] 

Other Information

ATC CodeL01XX44S01LA05
Related LinksKEGG